HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Revolution Medicines (NASDAQ:RVMD) and maintained a price target of $32.
October 26, 2023 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revolution Medicines has received a reiterated 'Buy' rating and a maintained price target of $32 from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Revolution Medicines. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100